Medinol

Another Interesting case presented by Dr. Paola García, Cardiovascular Center, CEDIMAT, Dominican Republic: "A 72-year-old female goes to the cardiology clinic due to chest pain and dyspnea. Paraclinical studies are performed that show data of ischemic heart disease, so she is taken to coronary angiography on an outpatient basis, revealing a severe lesion, with moderate calcification, long from the union of the proximal segment with the middle that involves the exit of the 1st diagonal which is a small caliber vessel but supplies an important territory with severe proximal and distal injury; being a Medina classification 1,1,1. We proceed to perform provisional stenting, we treat the 1st diagonal with medicated balloons and after predilatation with conventional balloons the anterior Descending lesion we proceed to place a first EluNIR-PERL stent followed by a second EluNIR-PERL stent overlapping the anterior one without any difficulty and less contrast due to the stent markers, even ending with post-dilatation of the stent guided by markers". #Innovation #EluNIRPERL #PatientOutcomes #HealthTech #cardiovascular #coronary #Medinol #MedicalDevices #Cardiology #Innovation #CardiovascularHealth #DrugElutingStent #StentInnovation #Medinol #HealthcareInnovation #PatientOutcomes #HealthTech #cardiovascular Smeling Baez

Interesting case presented by Prof. Haim Danenberg, head of interventional cardiology at the Wolfson Medical Center in Holon, Israel: "48 y-o admitted for a STEMI- treated with PCI - EluNIR-PERL DES to ostial LAD. 3 weeks after - PCI to ostial LCX. The markers on the EluNIR-PERL allow for precise deployment without risking the LM. An additional EluNIR-PERL in the mid LAD without touching Diagonal". This case highlights the importance of precision in interventional cardiology and the valuable role of the markers on the EluNIR-PERL in enhancing patient outcomes. #Innovation #EluNIRPERL #PatientOutcomes #HealthTech #cardiovascular #coronary

🎉 Exciting News! CE Approval for Medinol’s EluNIR-PERL™ Drug-Eluting Stent System 🎉 We are thrilled to announce that our innovative EluNIR-PERL™ DES has received CE approval! This marks a significant milestone in our commitment to advancing cardiovascular care and offering pioneering solutions to patients worldwide. The EluNIR-PERL™ DES is designed to enhance procedural precision and improve patient outcomes, building upon the proven performance of the EluNIR™ DES system. With unique features such as four radiopaque markers and a hybrid polymer-metal radiopaque catheter tip, the EluNIR-PERL™ ensures outstanding visualization during PCI procedures. This achievement reflects our dedication to excellence and innovation in medical device technology. We are proud to provide physicians with tools that not only meet but exceed the demands of modern interventional cardiology.   #Medinol #EluNIRPERL #MedicalDevices #Cardiology #Innovation #CEApproval #CardiovascularHealth #DrugElutingStent #StentInnovation #CEMark #Medinol #HealthcareInnovation #PatientOutcomes #HealthTech #cardiovascular #coronary

🌐 Exciting update! Yesterday, Dr. Raj Dave of Cardiovascular Experts of PA implanted the EluNIR - PERL DES. Dr. Dave noted, "The platinum marker on EluNIR - PERL allows accurate and precise placement in the most challenging coronary anatomy." A big thanks to the team at Cardiovascular Experts of PA for helping patients and saving lives through innovative technology. 🤝 In collaboration with CoSo Health, we’re excited to expand the reach of EluNIR - PERL to hospitals and ASCs across the U.S. and Brazil. #Cardiology #Innovation #EluNIRPERL #PatientOutcomes #HealthTech #cardiovascular #coronary

🫀 We Are Here at #EuroPCR2024! To schedule a meeting, send a message here 👆

💫 Exciting news! The #FDA has approved an Early Feasibility Study (EFS) for our innovative ChampioNIR™ Drug-Eluting Peripheral Stent System. This is a significant milestone in our mission to bring advanced solutions for treating peripheral artery disease. The EFS will allow us to evaluate the safety and performance of this novel stent technology in a clinical setting. We're grateful for this opportunity to further our research and development efforts. At Medinol, we remain dedicated to pioneering medical innovations that improve people's lives. Stay tuned for more updates on this exciting clinical program. #Innovation #Healthcare #MedTech #FDAApproval #EFS #ChampioNIR #DrugElutingPeripheralStent #ChampioNIRStent #Medinol #EFS #ClinicalProgram

✨ Happy Passover from Medinol! ✨

🌷 Happy Easter from Medinol 🌷 May this Easter bring new beginnings and fresh opportunities for all. To our valued customers and partners who celebrate, we extend our heartfelt Easter greetings. Your continued support means everything to us, and we are grateful to be part of your community. #Easter2024 #Gratitude #Easter2024 #NewBeginnings #innovation

👉 We're Hiring! Join Our Team Medinol is growing, and we're seeking talented individuals to join our innovative team. We're passionate about collaboration, creativity, and excellence, and are looking for driven professionals who want to make an impact. If you're interested in being part of our success, visit our JOIN US page at www.medinol.com to explore open roles and apply today. #hiring #jointheteam #engineering #engineer #researchanddevelopment ##innovation #medicaldevices #quality #regulation #finance

🌟 We extend our sincere thanks to Dr. Alfonso Torres, Head of the Hemodynamic Department at Araba University Hospital in Vitoria-Gasteiz, Spain, for being an invaluable part of the EluNIR DES showcase. It's collaborations like these that drive innovation and improve patient outcomes. A Special Thanks to World Medica! for flawlessly orchestrating an educational day at Araba University Hospital in Vitoria-Gasteiz, Spain. #MedicalInnovation #Cardiology #HealthcareLeadership #EluNIRDES #Gratitude #interventionalradiology